Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 75 years old
- People who have been diagnosed with primary liver cancer (hepatocellular carcinoma) or cancer that has spread to the liver from elsewhere, confirmed either by clinical assessment or tissue testing
- People whose liver tumours are each no larger than 5cm in size, and who have no more than 5 tumours in the liver
- People who do not have cancer that has spread outside the liver; for those with cancer that originally started elsewhere, the original cancer must have been fully removed with no sign of it coming back
- People whose liver function score (Child-Pugh score) is 7 or below, meaning the liver is still functioning at a reasonable level
- People who are largely able to carry out daily activities, with little or no limitation due to their illness (ECOG performance status 0 or 1)
- People who are expected to live for at least 3 months
- People who have previously had surgery, chemotherapy, targeted therapy, ablation, or other liver-directed or immune treatments, as long as the last treatment was at least 3 weeks ago
- People whose blood counts, liver function, kidney function, and blood clotting results meet specific laboratory thresholds set by the trial (confirm exact values with trial site)
- People with hepatitis B virus (HBV) levels above a certain threshold may still be considered, provided they are receiving appropriate antiviral treatment (confirm with trial site)
Who may not be able to join:
- People whose liver cancer is widespread throughout the liver, or where the cancer has grown into major blood vessels near the liver
- People with severe liver shrinkage, or where treating the tumours would require destroying more than one-third of the liver
- People with blood clotting problems that cannot be corrected, or serious blood disorders that raise the risk of bleeding
- People with an active bacterial or fungal infection at the time of enrolment
- People who have had, or currently have, another type of cancer (other than the cancer being studied in this trial)
- People who have had a solid organ transplant or who have a history of a brain condition caused by liver failure (hepatic encephalopathy)
- People who are currently taking part in another clinical trial, or who have previously received an experimental (unapproved) treatment
- People who are pregnant, breastfeeding, or planning to become pregnant
- People whom the trial investigators judge to be unsuitable for participation for any other reason (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lichao Xu, M.D, Fudan University
Phone: : +86-021-64175590
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression Free Survival (PFS); Assessment of immune activating response
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.